Key result
Preemptive oral midodrine (5 mg) did not significantly reduce orthostatic hypotension during mobilization 6 hours after hip arthroplasty compared with placebo (25.0% vs 39.7%; RR 0.63; P=0.095).
Why the study?
Does oral midodrine hydrochloride reduce the prevalence of orthostatic hypotension in patients undergoing total hip arthroplasty?
RCT (n=120)
Double-blind
randomized
Does oral midodrine hydrochloride reduce the prevalence of orthostatic hypotension in patients undergoing total hip arthroplasty?
Relative Risk: 0.63 (95% CI 0.36–1.1)
Absolute Event Rate: 25% vs 39.7%
p-value: p=0.095
Preemptive 5 mg oral midodrine did not significantly reduce orthostatic hypotension during early mobilization after hip arthroplasty.
Does not support preemptive midodrine for orthostatic hypotension prevention after hip arthroplasty; challenges efficacy hypothesis and directs research to alternatives.
BACKGROUND: Early postoperative mobilization is essential for rapid recovery but may be impaired by orthostatic intolerance (OI) and orthostatic hypotension (OH), which are highly prevalent after major surgery. Pathogenic mechanisms include an insufficient postoperative vasopressor response. The oral α-1 agonist midodrine hydrochloride increases vascular resistance, and the authors hypothesized that midodrine would reduce the prevalence of OH during mobilization 6 h after total hip arthroplasty relative to placebo. METHODS: This double-blind, randomized trial allocated 120 patients 18 yr or older and scheduled for total hip arthroplasty under spinal anesthesia to either 5 mg midodrine hydrochloride or placebo orally 1 h before mobilization at 6 and 24 h postoperatively. The primary outcome was the prevalence of OH (decrease in systolic or diastolic arterial pressures of > 20 or 10 mmHg, respectively) during mobilization 6 h after surgery. Secondary outcomes were OI and hemodynamic responses to mobilization at 6 and 24 h. RESULTS: At 6 h, 14 (25%; 95% CI, 14 to 38%) versus 23 (39.7%; 95% CI, 27 to 53%) patients had OH in the midodrine and placebo group, respectively, relative risk 0.63 (0.36 to 1.10; P = 0.095), whereas OI was present in 15 (25.0%; 15 to 38%) versus 22 (37.3%; 25 to 51%) patients, relative risk 0.68 (0.39 to 1.18; P = 0.165). At 24 h, OI and OH prevalence did not differ between groups. CONCLUSIONS: Preemptive use of oral 5 mg midodrine did not significantly reduce the prevalence of OH during early postoperative mobilization compared with placebo. However, further studies on dose and timing are warranted since midodrine is effective in chronic OH conditions.
No takes yet. Share an insight, caveat, or question.
Jans et al. (2015) conducted an RCT in Orthostatic hypotension after hip arthroplasty (n=120). Midodrine hydrochloride vs. Placebo was evaluated on Prevalence of orthostatic hypotension (decrease in systolic or diastolic arterial pressures of > 20 or 10 mmHg, respectively) during mobilization 6 h after surgery (RR 0.63, 95% CI 0.36 to 1.10, p=0.095). Preemptive oral midodrine (5 mg) did not significantly reduce orthostatic hypotension during mobilization 6 hours after hip arthroplasty compared with placebo (25.0% vs 39.7%; RR 0.63; P=0.095).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: